CHRONIC SPONTANEOUS URTICARIA

This study tests an experimental drug called BLU-808 for people with chronic hives (either triggered by heat/cold/pressure or happening without a clear cause) that don't get better with standard allergy pills. The drug works by blocking a protein called KIT, which may calm the im…

This study looks at the long-term safety and effectiveness of barzolvolimab for adults with chronic spontaneous urticaria (CSU), a condition causing frequent hives and itching. About 1,370 participants who finished earlier phase 3 trials will receive the drug and be monitored for…

This study follows about 3,280 adults with chronic spontaneous urticaria (long-lasting hives with no clear trigger) to see how well remibrutinib works in real-world clinics. Participants either stay on standard antihistamines or switch to remibrutinib, based on their doctor's dec…

This study tests a new drug called remibrutinib for teenagers aged 12 to 17 who have chronic hives (itchy welts) that don't get better with standard allergy pills. The goal is to see if the drug reduces itching and hives better than a placebo. Participants may continue the study …

This study looks at whether people with chronic spontaneous urticaria (long-lasting hives) who are doing well on omalizumab shots every 4 weeks can safely stretch the time between shots without losing control of their symptoms. About 40 adults whose hives are well-controlled will…

This program gives adults with chronic spontaneous urticaria (long-term hives) access to remibrutinib, an experimental drug. It is for people whose hives did not improve with standard treatments like antihistamines or omalizumab. The goal is to control symptoms and improve qualit…

This study looks at how well a new drug, remibrutinib, controls chronic hives (CSU) in everyday medical practice. About 505 adults whose hives are not controlled by standard antihistamines will be followed for 24 months. Researchers will track hive activity and control scores to …

This study tracks 350 adults with chronic spontaneous urticaria (long-lasting hives) who are starting a new medication called remibrutinib. Researchers will use patient questionnaires to measure how well the drug controls symptoms like itching and swelling over the first month. T…

This study tests a daily oral medication called ritlecitinib for adults with chronic spontaneous urticaria (CSU) — a condition causing itchy hives and deep skin swelling without a clear trigger. About 200 participants who haven't found relief from antihistamines will be randomly …

This early-stage study tests an experimental oral drug called EDP-978 in 98 healthy adults. The main goal is to check safety and how the drug moves through the body. It is the first time this drug is given to humans, and results will guide future studies for people with chronic h…

This early-stage study tests the safety of a new oral drug called HRS-3095 in 66 healthy adults aged 18-55. It measures how the drug moves through the body and its effects on certain enzymes. The goal is to gather safety data, not to treat any disease, which will help guide futur…

This study follows 400 people with chronic spontaneous urticaria (long-lasting hives) who are prescribed dupilumab by their doctor. Researchers will collect information from medical records and patient surveys over 24 months to see how well the drug works in everyday life, its sa…